Table 2.
Other locoregional and systemic treatments
| Characteristics | Gemcitabine/Cisplatin (n = 76) | HAIP, MSKCC (n = 192) | P-value |
|---|---|---|---|
| N (%) | N (%) | ||
| Prior systemic chemotherapy | – | 58 (30.2) | |
| Gemcitabine | – | 2 (1.0) | |
| Gemcitabine/oxaliplatin | – | 12 (6.3) | |
| Gemcitabine/cisplatin | – | 29 (15.1) | |
| Gemcitabine/capecitabine | – | 3 (1.6) | |
| Carboplatin/taxol | – | 3 (1.6) | |
| FOLFIRINOX | – | 5 (2.6) | |
| Other | – | 4 (2.1) | |
| Concurrent systemic chemotherapy | 76 (100) | 138 (71.9) | |
| Gemcitabine | – | 25 (13.0) | |
| Gemcitabine/oxaliplatin | – | 57 (29.7) | |
| Gemcitabine/cisplatin | 76 (100) | 0 (0.0) | |
| Irinotecan | – | 39 (20.3) | |
| Bevacizumab | – | 11 (5.7) | |
| Other | – | 6 (3.1) | |
| Locoregional treatmenta | 3 (3.9)b | 18 (9.4)c | 0.14 |
| Conversion to resection | 1 (1.3) | 13 (6.8) | 0.07 |
| Ablation (RFA, MWA, IRE) | 1 (1.3) | 2 (1.0) | 0.85 |
| TACE | 2 (2.6) | 3 (1.6) | 0.56 |
| External radiation | – | 1 (0.5) | 0.53 |
HAIP hepatic arterial infusion pump, Y90 yttrium-90, RFA radiofrequency ablation, MWA microwave ablation, IRE irreversible electroporation, TACE transarterial chemoembolization.
aLocoregional treatment after gem-cis or HAIP.
bOne patient was treated with both ablation and TACE.
cOne patient was treated with both ablation and resection.